Portal de Periódicos da CAPES

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

2016; American Association for the Advancement of Science; Volume: 352; Issue: 6288 Linguagem: Inglês

10.1126/science.aaf0972

1095-9203

Till Schoofs, Florian Klein, Malte Braunschweig, Edward F. Kreider, Anna Feldmann, Lilian Nogueira, Thiago Y. Oliveira, Julio C. C. Lorenzi, Erica H. Parrish, Gerald H. Learn, Anthony P. West, Pamela J. Björkman, Sarah J. Schlesinger, Michael S. Seaman, Julie Czartoski, M. Juliana McElrath, Nico Pfeifer, Beatrice H. Hahn, Marina Caskey, Michel C. Nussenzweig,

HIV/AIDS drug development and treatment

3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1.